![Ronit Harpaz. Ronit Harpaz.](https://pic1.calcalist.co.il/picserver3/crop_images/2024/07/11/ryBhbWpwA/ryBhbWpwA_0_91_1162_872_0_large.jpg)
Endoron Medical nets $10 million for lifesaving aneurysm repair innovations
Endoron Medical nets $10 million for lifesaving aneurysm repair innovations
New funding round to propel EndoStapling technology through critical clinical trials.
Endoron Medical, a medtech company that develops endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms (AAA), has announced the successful closing of its $10 million Series A funding round. The round was led by Sofinnova Partners, with substantial matching contributions from the European Innovation Council Fund (EIC Fund). This significant influx of capital is set to expedite the clinical validation of Endoron’s flagship product, the catheter-based EndoStapling solution Aortoseal, which is currently advancing through its Investigational Device Exemption (IDE) approved Early Feasibility Study (EFS).
Founded in 2019, Endoron Medical was established by a team of experts with extensive industry expertise and entrepreneurial experience. The founding team includes Ronit Harpaz, an Elite 8400 member and former CEO of Bendit Technologies; Prof. Ron Karmeli, a world-renowned vascular surgeon; and Eyal Teichman, a mechanical engineer with over 30 years of R&D experience.
Endoron technologies for the endovascular repair of AAAs addresses the critical challenges of sealing and securing endografts used in minimally invasive AAA repairs, particularly in complex procedures. Endoron’s advanced stapling mechanism ensures complete sealing of endografts while securely anchoring them, preventing long-term migration and endoleaks, and thereby reducing the need for highly invasive, high-mortality open surgeries.
"Sofinnova Partners are the go-to investors within medtech. They bring a wealth of operational experience working with high-growth companies like ours," said Ronit Harpaz, co-founder and CEO of Endoron. "With their continued support, I am confident we will reach key clinical and regulatory milestones as we advance our EndoStapling technology towards the clinic. The EIC’s participation further solidifies our commitment to bringing this innovative solution to the European market."